Enforced expression of B cell lymphoma oncogenes such as MYC, NMYC or BCL2, in the B cell compartment or loss of tumor suppressors can also skew MuLV driven malignancies toward B cell lymphoma and leukemias (22–26). This evidence concerns the gene BCL2 and leukemia.